HER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer

Azadeh Stark, Barbara S. Hulka, Scott Joens, Debra Novotny, et al
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001

Share article


Reviewers: Li Liu, MD
Source: Journal of Clinical Oncology, Volume 18, No. 2 (January): 267-274, 2000

Background

The HER-2/neu oncogene (also called c-erbB-2) codes a surface membrane protein that interacts with the epithelial growth factor receptor. Several studies have reported an association between HER-2/neu amplification and both earlier relapse and decreased survival in patients with breast cancers. The clinical significance of HER-2/neu expression in benign breast lesions (BBL) remains unclear. This study assessed the amplification of the HER-2/neu gene in BBL and risk of subsequent breast cancer.

Methods

The investigators measured HER-2/neu gene expression in benign and malignant breast tissues from 137 women with BBL who subsequently developed breast cancer, and in benign tissue from 156 controls with BBL who did not develop cancer.

Results

  • Low-level HER-2/neu amplification was detected in 4.5% of benign biopsies from control women, compared with 9.5% of benign tissues and 18% of malignant tissues from breast cancer patients.
  • In women with both HER-2/neu amplification and a proliferative histopathologic diagnosis, the risk of breast cancer was increased more than seven-fold.
  • Overexpression of HER-2/neu protein was more common in tissues from breast tumors than in benign breast tissue samples.
  • Women with HER-2/neu gene amplification in their malignant tumors were also likely to have HER-2/neu gene amplification in earlier, benign breast samples.

Discussion

Genetic alterations, including HER-2/neu gene amplification, may occur as relatively early events in the development of breast cancer. This finding may help physicians to identify the subgroup of women with benign breast lesions who may be at higher risk of developing breast cancers.


News
Adverse Prognostic Factor ID'd in Operable Breast Cancer

Oct 31, 2012 - For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 is an adverse prognostic factor, according to a study published online Sept. 4 in The Oncologist.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información